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Abstract Diffuse large B-cell lymphoma (DLBCL) consti-
tutes most primary central nervous system (CNS) lym-
phoma (PCNSL), whereas T-cell, low-grade and Burkitt’s
lymphomas (BL) are rarely encountered. Due to the
paucity of cases, little is known about the clinical
features and treatment outcomes of PCNSL other than
DLBCL. The objective of this study was to describe the
clinical characteristics and outcomes for patients with
PCNSL other than DLBCL. Fifteen patients, newly
diagnosed with PCNSLs other than DLBCL between
2000 and 2010, were included. The male to female ratio
was 0.67:1 with a median age of diagnosis of 31 years
(range 18–59). Pathologic distributions were as follows:
peripheral T-cell lymphoma (PTCL; n=7), marginal zone
B-cell lymphoma (MZBCL; n=1), lymphoplasmacytic
lymphoma (LPL; n=2), Burkitt’s lymphoma (n=1), other
unspecified (T-cell lineage, n=2; B-cell lineage, n=2).
Thirteen patients (87%) showed Eastern Cooperative
Oncology Group performance score (ECOG PS) 1–2.
The remaining two were one PTCL patient and one
Burkitt’s lymphoma patient. Of the nine patients with T-
cell lymphoma, five (56%) had multifocal lesions, and one
(20%) with LPL of the five patients with B-cell lymphoma
showed a single lesion. Leptomeningeal lymphomatosis
was identified in two patients (one with Burkitt’s lympho-
ma and one with unspecified B-cell lymphoma). Two
patients (22%) with T-cell lymphoma died 7.7 and
23.3 months later, respectively, due to disease progression,
despite HD-MTX-based therapy. Six patients with T-cell
lymphoma (6/9, 66.7%) and four patients with low-grade
B-cell lymphoma (4/5, 80%) achieved complete response
and have survived without relapse (Table 3). One patient
with Burkitt’s lymphoma showed poor clinical features
with ECOG PS 3, deep structure, multifocal, and lep-
tomeningeal lymphomatosis, and died 7.6 months after the
initiation of treatment. In comparison with previously
reported DLBCLs (median OS 6.4 years, 95% CI 3.7–
9.1 years), T-cell lymphoma showed equivocal or favor-
able clinical outcomes and low-grade B-cell lymphomas,
such as MZBCL and LPL, had a good prognosis.
However, primary CNS Burkitt’s lymphoma presented
poor clinical outcomes and showed a comparatively
aggressive clinical course. In conclusion, primary CNS
lymphoma other than DLBCL occurred more in younger
patients and showed a generally good prognosis, except
for Burkitt’s lymphoma. Further research on treatment
strategies for Burkitt’s lymphoma is needed.
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Introduction
Primary central nervous system (CNS) lymphoma (PCNSL)
is a rare variant of extranodal non-Hodgkin’s lymphoma
that occurs in the brain, leptomeninges, spinal cord, or eyes
without evidence of systemic disease. It is an aggressive
disease with a median survival time of 1.5–3.3 months in
untreated patients [20, 23]. PCNSL accounts for approxi-
mately 4% of all primary brain tumors and 4–6% of
extranodal lymphomas [23]. Diffuse large B-cell lymphoma
(DLBCL) is the most common type (>90%) of PCNSL,
whereas approximately 10% are T-cell lymphomas (<5%),
poorly characterized low-grade lymphomas and Burkitt’s
lymphoma (BL). Few case reports have been described in
the literature [1, 2, 17]. According to the World Health
Organization (WHO) classification [30], primary DLBCL
of the CNS was categorized as a subclassification of the
DLBCL rather than as a separate entity due to indistin-
guishable morphology from systemic DLBCL. However,
the remaining T-cell or other B-cell lymphomas of the CNS
are not mentioned, and little is known about their clinical
features and treatment outcomes because of their rarity.
Therefore, we reviewed our experiences to analyze clinical
features and treatment outcomes of 15 patients with rare
primary CNS lymphoma other than DLBCL.
Patients and methods
Patients
Fifteen patients diagnosed with PCNSL other than
DLBCL from January 2000 to July 2010 were included
in this analysis. No patients had been in immunocom-
promised states brought about by, for example, organ
transplantation or HIV infection. The pathologic diagno-
sis of PCNSL was based on the WHO classification after
surgical resection. To evaluate the T- or B-cell lineage of
PCNSL, immunohistochemical analysis was performed;
and to confirm the T- or B-cell lineage of the tumors,
TCR-γ gene and immunoglobulin heavy chain gene
rearrangements were examined. The clinical information
of patients, including age, sex, symptoms, physical
findings, diagnostic procedures, and treatment was
retrieved from our electronic medical records. Laboratory
findings at diagnosis, such as blood cell counts,
chemistry profile, serum protein electrophoresis, serum
lactate dehydrogenase (LDH), serology of hepatitis B, C
and HIV, and CSF laboratory findings, such as cell
counts, protein, glucose, LDH and cytology, and bone
marrow examinations were reviewed. Through meticu-
lous physical examination including Waldeyer’s ring,
chest and abdomino-pelvic computed tomography (CT),
and positron emission tomography-CT, patients who had
other primary sites of lymphoma were excluded.
Treatment
Data regarding treatment regimens and clinical courses for
each patient were extracted from the review of medical
records. The treatment course and response of each patient
are summarized in Table 3. Treatment cohorts were generally
divided into two groups in accordance with the chemotherapy
regimen of our institution. Cohort 1[3], diagnosed prior to
December 2002, was treated with 1 g/m2 of intravenous
MTX (HD-MTX 1 g/m2 regimen) on days 1 and 8, in
addition to 12 mg of intrathecal MTX via an Ommaya
reservoir on days 1, 4, 8, 11, 15, and 18. This was followed
by whole-brain irradiation (WBRT) and an additional 7.2–
14.4 Gy boost to primary tumors. All patients received
WBRT, regardless of age. WBRT is a parallel-opposing
technique using 4- or 6-MV photons. The median dose was
40 Gy (range 18–50 Gy) in a daily fraction of 2 Gy. After
radiotherapy, two cycles of intravenous cytosine arabinoside
(HiDAC) at a dose of 3 g/m2 on two consecutive days
was administered. Leucovorin (25 mg intravenously or
orally, every 6 h) was given starting 24 h after intravenous
MTX, until the plasma MTX concentration fell below
10−7 M. Cohort 2 [4], diagnosed from January 2003, was
treated with five cycles of 3.5 g/m2 of intravenous MTX
(HD-MTX 3.5 g/m2 regimen) and vincristine 1.4 mg/m2 at
2-weekly intervals, with/without procarbazine 100 mg/m2
for 7 days on cycles 1, 3, and 5. Intrathecal MTX (12 mg)
was given via an Ommaya reservoir at 2-weekly intervals
on the alterative weeks of intravenous MTX for five
cycles. After the intravenous and intrathecal MTX
schedules, a total dose of 30–45 Gy (median 45 Gy) was
delivered to the whole brain with the same technique used
in cohort 1. Patients with ocular involvement received
additional ocular radiotherapy at 30–40 Gy. After com-
pletion of WBRT, the majority of patients were treated
with HiDAC, as in cohort 1. For patients 60 years and
older, WBRT was deferred.
Response evaluation
We reassessed the treatment response in accordance with
the International Primary CNS Lymphoma Collaborative
Group Guidelines for Response Assessment for Clinical
Trials [1]. Complete response (CR) was defined as non-
enhancing disease with normal eye examination and
negative CSF cytology. Unconfirmed complete response
was defined as minor-enhancing disease or minor retina
pigment epithelial abnormality with negative CSF cytology.
Partial response was defined as a 50% decrease in
enhancement regardless of minor retina pigment epithelial
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abnormality with negative CSF cytology. Progressive
disease was defined as a 25% increase in enhancement/
new site or recurrent/new disease on eye examination or
recurrent/positive CSF cytology. Stable disease (SD) was
defined as other scenarios not covered by the above
criteria. Assessment of treatment response was evaluated
at least twice by brain magnetic resonance imaging at the
time point between the completion of intravenous and
intrathecal MTX and the start of WBRT and/or high-dose
cytarabine, and after completion of the planned treatment




The main clinical characteristics of patients at diagnosis are
summarized in Table 1. There were six male and nine
female patients with a median age of diagnosis of 31 years
(range 18–59). According to the WHO classification,
histopathologic distribution is shown in Table 3 and as
follows: peripheral T-cell lymphoma (PTCL; n=7), mar-
ginal zone B-cell lymphoma (MZBCL; n=1), lymphoplas-
macytic lymphoma (LPL; n=2), BL (n=1), and other
unspecified (T-cell lineage, n=2/B-cell lineage, n=2).
PTCL was characterized by a population of predominantly
small-sized cells admixed with occasional medium-sized
cells positive for polyclonal CD3 antibody, representing a
T-cell character of the tumor. The tumors of MZBCL were
identical to those of MZBCLs in other sites. They were
composed of sheets of small- to medium-sized lymphocytes
with moderate amounts of cytoplasm and irregular nuclei,
bearing a close resemblance to the small-cleaved cells or
centrocytes of the lymphoid follicles. The neoplastic cells
were immunoreactive for CD20 and CD79a and did not
express CD3, CD5, CD10, or Cyclin D1. No evidence of
amyloid deposition was present. Immunoglobulin light
chain restriction was detected. No definitive features of
transformation to a more aggressive histology were evident.
The characters of LPL were immunoreactive for B-cell
markers CD20, and negative for the T-cell marker CD3 and
bcl. Immunoreactivity for the kappa chain was positive in
the one patient. These pathologic findings were consistent
with a lymphoplasmacytic lymphoma. Histopathologic
examination of BL showed a distinct starry-sky pattern
caused by interspersed tangible body macrophages and a
diffuse monotonous infiltrate of medium-sized cells with a
slight molding pattern. Immunohistochemical analysis
revealed the tumor cells expressed LCA, CD10, CD20,
and CD79a, but not CD3, CD45RO, CD30, panCK,
CD117, BCL2, BCL6, synaptophysin, chromagranin, S-
100 protein, and CD68. The tumor cells also displayed
strong and diffuse nuclear positivity of Ki-67.
Most patients initially presented with neurologic symp-
toms such as headache/vomiting (31.3%), extremity weak-
ness (40%), and facial nerve palsy (13.3%), but without B-
cell symptoms such as fever, night sweats, and weight loss.
Most patients showed good performance status of ECOG
PS 1–2 and two patients had ECOG PS grade 3–4. Eight
patients (53.3%) had the disease confined to only the
cerebral hemisphere. Six patients (40%) were diagnosed
with deep structure lesions such as the medulla (n=2),
medulla with spinal cord involvement (n=1), basal ganglia
with hippocampus (n=1), thalamus (n=1), and corpus
callosum (n=1) and one patient had only a single spinal
cord lesion. Multiple lesions (more than two lesions) were
detected in six patients (40%). Positive tumor cells in the
CSF were found in two patients, including one with
Table 1 Patients characteristics (N=15)
Characteristics No. of patients Percentage
Age












Burkitt’s lymphoma 1 6.7
B symptoms 0 0
Neurologic symptoms
Headache/vomiting 5 31.3
Extremity Weakness 6 40
Paresthesia 1 6.7
Seizure 1 6.7
Facial nerve palsy 2 13.3
Site of disease
Cerebral hemisphere 8 53.3
aDeep structures 6 40
Spinal cord 1 6.7
Multiple lesions 6 40
CSF cytology 2 13.3
High CSF protein 7 46.7
High CSF LDH 8 53.3
High serum LDH 3 20
a Basal ganglia, brainstem, corpus callosum, and cerebellum
Ann Hematol (2011) 90:1391–1398 1393
leptomeningeal enhancement of brain MRI. Seven patients
(47%) had an elevated concentration of CSF protein, and
eight patients (53.3%) had high CSF LDH. Three patients
(20%) had an elevated serum LDH level. To facilitate
comparison with DLBCL, brief characteristics are shown in
Table 2 alongside those of the 50 primary CNS DLBCL
patients reported by Uhm et al. [32]. PCNSL other than
DLBCL showed a tendency to occur in younger patients.
More than half of those with T-cell lymphoma developed
multifocal lesions. However, among nine cases of T-cell
lymphoma, none had positive CSF cytology, compared
with two B-cell lymphoma patients with positive CSF
cytology (one with Burkitt’s lymphoma and one with
low-grade lymphoma).
Treatments and outcomes
The median follow-up time was 39 months (range 1–
123 months). PCNSL other than DLBCL did not reach the
median survival to date. Data of treatments and clinical
outcomes of all patients are shown in Table 3. Of the nine
patients with T-cell lymphoma, six patients (66.7%)
achieved CR and one patient was alive at 2.5 months with
SD. Of the five patients with low-grade B-cell lymphoma,
three (60%) achieved CR and one patient was alive at
2.6 months with SD. One patient with LPL of one spinal
cord lesion confined to T4 had surgical corpectomy and
achieved CR without adjuvant chemotherapy. One patient
with Burkitt’s lymphoma died at 7.6 months despite HD-
MTX-based chemotherapy.
Discussion
We analyzed PCNSL other than DLBCL, which is the most
common type of PCNSL, in a single institution. There are
few reports about primary CNS T-cell lymphoma, anaplas-
tic large cell lymphoma, low-grade lymphoma, and
Burkitt’s lymphoma [6, 9, 14, 21, 24, 26, 27, 31]. The
incidence of those lymphomas is unknown precisely
because of its rarity. It is known that in immunocompetent
patients, the median age at diagnosis of PCNSL is
53–57 years. The highest risk group is those 60 years and
older [25], and the male to female ratio is 1.2–1.7:1.
However, in this study, the median age of PCNSL other
than DLBCL was 31 years (range 18–59) with a male-to-
female ratio of 0.67:1. In Western countries, TPCNSL has
been reported to constitute less than 4% of all PCNSLs, but
in a nationwide survey of PCNSL in Japan, 8% of all cases
were of T-cell origin [5, 12, 28]. Out of 121 consecutive
PCNSL patients that we have followed up in our center
during the last 10 years, nine PCNSL patients had T-cell
lymphoma (7.4%), and most of them were PTCL,
including two patients with unspecified T-cell lineage.
The incidence of TPCNSL in our study is more
comparable with Japanese than Western data. These data
may correlate with a generally higher incidence of T-cell
lymphomas in Far Eastern regions [16]. Shenkier et al.
reported that among 45 patients, involvement of deep
brain structures was seen in 16 patients (36%) and
multiple lesions in 13 patients (29%) at diagnosis [27].
In our study, of the nine patients with TPCNSL, three
(30%) had deep structures and five (56%) had multiple
lesions. Three patients (#6, 7, 8) had deep locations of
disease sites and presented with multiple lesions at the
same time. The prognosis for T-cell lymphoma is
controversial. There are several reports about primary
TPCNSL with poor prognosis [18, 19, 29], and several
with good response rates and overall survival time
[10, 27]. Of our sample of nine patients, two died due to
progressive disease after HD-MTX-based chemotherapy.
The remaining six patients are alive in CR except one
Table 2 Patients characteristics compared with 50 cases of PCNS DLBCL [32]
Characteristics T-cella (N=9) B-cell other than DLBCL (N=5) Burkitt’s lymphoma (N=1) DLBCL (N=50)
Age 33 (18–59) 44 (20–58) 43 51(19–78)
Male/Female 2/7 4/1 0/1 30/20
ECOG
0–2 8 (89%) 5 (100%) 34 (68%)
3–4 1 (11%) 1(100%) 16 (32%)
Deep structure 3 (33%) 2 (40%) 1(100%) 39 (78%)
Multifocal 5 (56%) 1 (20%) 1(100%) 33 (66%)
CSF cytology 0 (0%) 1 (20%) 1(100%) 19 (38%)
DLBCL diffuse large B cell lymphoma
T-cell: seven peripheral T cell lymphoma, two unspecified T-cell lymphoma
B-cell other than DLBCL: one marginal zone B-cell lymphoma, two lymphoplasmacytic lymphoma, two unspecified B-cell lymphoma
a DLBCL, data from Uhm et al.[32]
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patient with SD at the 2.5-month follow-up. Although we
could not draw conclusions on the prognosis of TPCNSL
because of retrospective data and small patient numbers,
our data showed equivocal or favorable clinical outcomes
when compared with patients with DLBCL. It is
meaningful that our study population was treated in a
similar manner with HD-MTX-based treatment plus
radiotherapy.
Uncommonly, MZBCL may present as a slowly
growing localized mass arising from meningothelial
cells of the dura (primary dural lymphoma), especially
of the cerebral convexity, with rare cerebral parenchy-
mal infiltration [13]. The origin site was not the dura but
a single lesion of the thalamus. It is known that MZBCL
is very radiosensitive. Treatment options for primary
CNS MZBCL have ranged from local therapy to a
combination with systemic chemotherapy [22]. Iwamoto
et al. reported that eight patients with CNS MZBCL
achieved complete response to treatment and no patient
developed CNS recurrence during a median follow-up of
2 years (range 0.7–8.9 years). However, three patients
developed systemic relapse after a median of 6.8 years
(range 0.9–7.5 years). Bayraktar et al. showed that of six
patients with primary CNS MZBCL, four achieved
complete remission, and one relapsed at the same site
after 5 years [6]. The results show that primary CNS
MZBCLs display indolent clinical behavior and have a
generally favorable clinical outcome with long-term
disease control and survival. In our study, one patient
(#10) received systemic chemotherapy and radiotherapy
and is alive in complete remission at 39.4 months. Our
study also showed that primary CNS MZBCL had a good
prognosis despite involvement of a deep structure
(thalamus). A review of the literature indicates that local
therapy with radiation alone shows favorable outcomes
(Table 4). Given these results, local treatment alone can
be considered to be an effective modality for primary
CNS MZBCL.
We found two reports of primary CNS LPL [7, 15].
Carrasco et al. reported a pituitary LPL patient maintained
complete remission for 4 years after transsphenoidal
surgery, chemotherapy, and radiotherapy [7]. We experi-
enced one patient with a spinal cord LPL at T4 level. The
patient (#12) received only surgical resection (corpectomy)
without neurologic sequela and has lived without relapse
for 51 months. Another patient, with LPL at the corpus
callosum and left frontal lobe, is receiving the cohort 2
regimen. The interim evaluation is SD at 2.6 months. For
these two patients, the prognosis of LPL seems to be
satisfactory. Two patients did not show systemic symptoms
Table 3 Treatments and outcomes




01 F/59 1 PTCL Rt. frontal No/no Resection 2 CR AIR 22.9+
02 F/37 1 PTCL Rt. Frontoparietal No/no Biopsy 1 CR AIR 118.7+
03 F/34 2 PTCL Rt. Frontoparietal,
occipital
YES/no Resection 2 PD DOD 23.3
04 F/33 2 PTCL Rt. parietal, occipital,
temporal
Yes/no Biopsy 1 CR AlR 121.2+
05 M/31 1 PTCL Rt. occipital No/no Biopsy 1 CR AlR 121.6+
06 M/22 4 PTCL Medulla,Spinal cord,
Lt.parietal lobe
Yes/no Biopsy 2 SD AWD 2.5+
07 F/18 1 PTCL Basal ganglia,
Hippocampus
Yes/no Biopsy 2 CR AIR 15.3+
08 F/26 2 T-lineage Medulla, Both. frontal
Lt. temporal
Yes/no Biopsy 2 PD DOD 7.7
09 F/46 1 T-lineage Frontoparietal No/no Resection 1 CR AIR 123.8+
10 M/57 1 MZBCL Thalamus No/no Biopsy 2 CR AlR 39.4+
11 M/26 2 B-lineage Rt. Frontoparietal No/yes Biopsy 1 CR AIR 103.5+
12 M/50 2 LPL T4 Spinal cord No/no Resection Corpectomy CR AIR 51.0+
13 M/38 1 LPL Corpus callosum,
Lt. frontal
Yes/no Biopsy 2 SD AWD 2.6+
14 F/43 3 BL Medulla, LEMS No/yes Biopsy 2 PD DOD 7.6
15 F/20 1 B-lineage Lt. parietal No/no Biopsy 2 PD F/L 78.4
PTCL peripheral T-cell lymphoma, MZBCL marginal zone B-cell lymphoma, LPL lymphoplasmacytic lymphoma, BL Burkitt’s lymphoma, LEMS
leptomeningeal seeding, CR complete response, PR partial response, SD stable disease, PD progressive disease, AIR alive in remission, AWD alive
with disease, DOD dead of disease, F/L follow-up loss, Tx treatment, ECOG PS Eastern Cooperative Oncology Group performance score
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and signs such as IgM paraproteinemia, neuropathy, and
hyperviscosity.
Since Valsamis described the first case of primary
CNS Burkitt’s lymphoma in an infant in 1976 [33], there
have been several case reports of primary CNS Burkitt’s
lymphoma [11]. The reported data showed poor clinical
outcome. In our institution, one patient was diagnosed
with primary CNS Burkitt’s lymphoma at the medulla and
a leptomeningeal lesion with positive tumor cells in the
CSF. Although the patient received HD-MTX-based
chemotherapy, the final response was poor and the patient
died at 7.6 months with progressive disease. Given other
reports that show a poor outcome of primary CNS
Burkitt’s lymphoma, HD-MTX-based chemotherapy does
not appear to have an efficacious outcome. Therefore,
more effective and aggressive treatment approaches for
CNS Burkitt’s lymphoma are needed. In the literature
review with our data, low-grade B-cell lymphoma, such as
MZBCL and LPL, showed good prognosis, whereas
Burkitt’s lymphoma showed an unfavorable clinical
outcome (Table 4).
Reported 5-year survival rates after conventional
treatment with HD-MTX, either as a single agent or in
combination, followed by WBRT, is close to 40% [8].
Although heterogeneous and small number of cases does
not warrant that these disease entities has the good
prognosis than DLBCL, primary CNSLs, T-cell or B-cell
lymphoma, other than DLBCL showed satisfactory
treatment outcome in our series except for Burkitt’s
lymphoma.
In this study, we described our experiences of primary
CNS lymphoma other than DLBCL and made a historical
comparison with previously reported DLBCL data from
our institute. T-cell lymphoma showed equivocal or
favorable clinical outcomes, and low-grade B-cell lym-
phomas such as MZBCL and LPL showed a good
prognosis. However, CNS Burkitt’s lymphoma is more
aggressive and presents a poor clinical outcome. Further
research about treatment strategies for Burkitt’s lympho-
ma is needed. Additional analysis with a larger study
population, including patients from other institutes,
should be warranted.





Histology Location Surgery Chemotherapy Radiotherapy Outcome





WBRT (45 Gy) CR for
6.6 years
Partial seizure 33/F MZBCL Lt. forntal and
temporal
Biopsy IT MTX, IT cytarabine WBRT (30 Gy) CR for
7.2 years
Headache 35/M MZBCL Lt. tentorium and
frontoparietal
Biopsy IT thiopeta, HD-MTX,
vincristine, temozolomide,
Rtituximab




47/M MZBCL Lt. tentorium Partial
resection




Headache ? MZBCL Lt. lateral ventricle,
cavernous sinus
None WBRT (16 Gy),
IMRT (36 Gy)
CR for 4 years
Seizure ? MZBCL Frontal, occipital CTX AZT+HD-MTX CR for 5 years
Blurred vision ? MZBCL Bilateral intraocular Bilateral
vitrectomy
DeAngelis protocol Orbital RT CR for
6 months
Park et al. [6] Facial nerve
palsy
18/M MZBCL Lt. basal ganglia Biopsy RT CR for
1..8 months
Carrasco et al. [2] headache 49/F LPL Pituitary Biopsy HD-MTX, IT MTX,
HD-cytarabine
IMRT (30 GY) CR for 4 years
Kobayashi et al.
[4]




Vertigo 40/M BL Cerebellum and
pons
Biopsy HD-MTX WBRT CR for 1 year
Wilkening et al.
[8]
Back pain 43/F BL Epidural lesion at
the L2- L3




IMRT CR for 2 years
Monabati et al.
[5]




MZBCL marginal zone B-cell lymphoma, LPL lymphoplasmacytic lymphoma, BL Burkitt’s lymphoma, IT intrachecal, MTX methotrexate, AZT
azacytidine, CHOP cyclpphosphamide, doxorubicin, vincristine, prednisolone, WBRT whole brain radiation therapy, IMRT intensity modulated
radiation therapy, CR complete remis
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